As reported earlier, Prescrire had been sued by the manufacturer of tacrolimus ointment (Protopic®) on the grounds of "denigration" and claiming an "erroneous, or even deceitful, nature of certain critiques contained in the disputed article".
The Tribunal de Grande Instance de Paris rejected the case stating that Prescrire "did not exceed the legitimate objective that it had set for itself, nor the expectation on the part of its subscribers to have access to a documented critical analysis on a subject which falls into the domain of public interest and healthcare safety".
Prescrire note that this ruling supports the right to criticise provided that such criticism is supported by a rigorous and fully documented analysis.
Action: This ruling is welcome and supports the future of independent critical analysis of evidence to produce drug reviews.
|« SMC Update - March 2011 [updated]||Contraceptive interaction guidance »|